The name's still the thing for biosimilars
This article was originally published in SRA
What's in a name? A lot, it seems, when it comes to the identification of biosimilar medicines. Should they have the same INN as the reference product, or a different one to help track the right drug down in the event of safety issues? You'd think the issue would have been settled by now, but like so much else in the biosimilars area, uncertainties still abound.